AQR Capital Management
TRVI icon

AQR Capital Management’s Trevi Therapeutics TRVI Stock Holding History

AQR Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,149
Closed -$336K – 3968
2026
Q1 		$336K Sell
28,149
-1,053
-4% -$11.8K ﹤0.01% 3351
2025
Q4 		$366K Sell
29,202
-13,608
-32% -$157K ﹤0.01% 3079
2025
Q3 		$392K Buy
42,810
+17,980
+72% +$135K ﹤0.01% 2938
2025
Q2 		$136K Sell
24,830
-2,890
-10% -$18K ﹤0.01% 3129
2025
Q1 		$174K Buy
27,720
+4,688
+20% +$22.4K ﹤0.01% 2917
2024
Q4 		$94.9K Buy
+23,032
New +$73.7K ﹤0.01% 2769

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

AQR Capital Management's TRVI Position: Q2 2026 in Review

AQR Capital Management sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 28,149 shares — an estimated $336K sold.

AQR Capital Management first reported a position in TRVI in Q4 2024 and held it in 6 quarters. The position peaked at $392K in Q3 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • AQR Capital Management reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • AQR Capital Management sold 28,149 Trevi Therapeutics shares in Q2 2026, an estimated $336K.
  • AQR Capital Management first reported a position in Trevi Therapeutics in Q4 2024 and held it in 6 quarters.
  • AQR Capital Management's Trevi Therapeutics position peaked at $392K in Q3 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.